Increased the risk of heart failure and comorbidities in patients with gout treatment: a population-based cohort
Hsin-Hung Chen1,2, Ming-Chia Hsieh1,3,4, Chun-Wei Ho1
1Intelligent Diabetes Metabolism and Exercise Center, China Medical University Hospital, Taichung.
Insights
Gout patients have a significantly higher risk of developing heart failure (HF). Gout treatment, particularly combination therapy, may further increase this risk, highlighting a public health concern.
Area of Science:
- Cardiovascular Medicine
- Rheumatology
- Public Health
Background:
- Gout is a common inflammatory condition.
- Heart failure (HF) is a significant global health burden.
- The relationship between gout treatment and HF risk requires investigation.
Purpose of the Study:
- To examine the association between gout and the incidence of heart failure (HF).
- To evaluate the impact of gout treatment on HF risk.
Main Methods:
- A cohort study of 50,166 patients with gout (2000-2010).
- Utilized multivariable Cox proportional hazard regression and Kaplan-Meier methods.
- Assessed new HF diagnoses as the primary outcome.
Main Results:
- Gout patients exhibited a 1.96-fold higher incidence of HF compared to non-gout individuals.
- Increased HF risk was associated with age and being female.
- Receiving multiple anti-gout drug treatments correlated with higher HF incidence.
Conclusions:
- Gout is an independent risk factor for developing heart failure.
- Current gout treatment strategies in Taiwan may not mitigate, and could potentially elevate, HF risk.
- Addressing the public health impact of gout is crucial.
Background:
To investigate the association between gout treatment and heart failure (HF).
Methods:
Patients with gout between 2000 and 2010 constituted the gout cohort. The main outcome was a new diagnosis of HF. Multivariable Cox proportional hazard regression models were used to measure the effect of gout on the risk of developing HF. The Kaplan-Meier method was used to estimate the cumulative HF incidence curve for the gout and nongout cohorts.
Results:
The cohort study included 50,166 patients with gout. The incidence of HF was 1.96 times higher in the gout cohort than the non-gout cohort (7.11 vs. 3.63 per 10,000 person-years). The adjusted HR of developing HF was a 1.06-fold increase (95% CI: 1.06-1.07) with age and a 1.08-fold increase for women compared with men (95% CI: 1.02-1.14). HF incidence was higher in patients with receiving any two or more types of anti-gout drug treatment.
Conclusions:
Our study revealed that gout could increase the risk of HF. Gout treatment in Taiwan cannot improve HF and actually increase the risk for HF after combination therapy for gout. The public health burden of gout should be resolved in the future.
Related Concept Videos
01:24Chronic Kidney Disease II: Clinical Manifestations
01:22Heart Failure Drugs: Diuretics
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:21Rheumatic Heart Disease III: Medical Management
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...